Auma Surgery, University Hospital, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany; [email protected] (M.K.); [email protected] (A.K.); [email protected] (C.B.) SarKUM, Center of Bone and Soft Tissue Tumors, University Hospital, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany; [email protected] (L.H.L.); [email protected] (S.N.); [email protected] (T.K.); [email protected] (A.B.-M.) Division of Medicine III, University Hospital, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany Institute of Pathology, University Hospital, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany Division of Radiology, University Hospital, Ludwig-Maximilians-University Munich, D-81377 Munich, Germany Correspondence: [email protected]: Kirilova, M.; Klein, A.; Lindner, L.H.; Nachbichler, S.; Kn el, T.; Birkenmaier, C.; Baur-Melnyk, A.; D r, H.R. Amputation for Extremity Sarcoma: Indications and Outcomes. Cancers 2021, 13, 5125. https:// doi.org/10.3390/cancers13205125 Academic Editors: Robert J. Canter and Steven W. Thorpe Received: 22 1-Dodecanol-d25 Epigenetic Reader Domain August 2021 Accepted: 9 October 2021 Published: 13 OctoberSimple Summary: Sarcomas are malignant tumors of soft tissues or bone. When limb salvage surgery (LSS) will be the common therapy, amputation is an solution especially in regional recurrence (LR) or complications just after LSS. Two groups with major amputations (n = 120) or secondary amputations just after failed LSS because of LR or complications (n = 29) were compared. Five-year LR-free Aderbasib Inhibitor survival was 84 and 17 (16 ) individuals developed LR, of which 16 have been in group I and only one in group II. All round survival (OS) at 5 years was 44 , as well as the price was identical in both groups. In those group II sufferers who had a secondary amputation right after LSS on account of contaminated margins or LR (n = 12) five-year OS was 33 compared to 48 in patients with complications (n = 17). This study indicates the worse oncological outcomes with respect to OS of sarcoma individuals needing an amputation as in comparison with LSS. Patients with principal amputation or individuals who had a secondary amputation just after failed LSS for what ever purpose showed the identical outcomes. Abstract: Background: Sarcomas are rare, malignant tumors of soft tissues or bone. Limb salvage surgery (LSS) would be the typical treatment, but amputation is still an solution, especially in local recurrence or complications right after LSS. Strategies: We retrospectively reviewed indications and oncological outcomes in individuals who underwent an amputation. Two groups with either main amputations (n = 120) or with secondary amputations just after failed LSS with local recurrence or complications (n = 29) have been compared with all the primary end points of LRFS and OS. Benefits: Five-year LRFS was 84 with 17 (16 ) patients creating neighborhood recurrence, of which 16 (13 ) occurred in group I. Forty-two (28 ) individuals developed metastatic illness and overall survival at five years was 44 . General survival (OS) was precisely the same in each groups. In those group II sufferers who had a secondary amputation as a result of LR or insufficient margins just after LSS (n = 12) the five-year OS was 33 in comparison to 48 in sufferers with amputation because of complications (n = 17) (n.s.). Conclusions: This study indica.
